Marius Pharmaceuticals, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersRaleigh, NC
US patents31
SAM.gov UEIXJP7M618A5Q8
CAGE code9M0N6
Incorporated inDE
- therapies
- testosterone deficiency
- KYZATREX
- adult men
- low testosterone
- medical conditions
- hormone health
- improving
- well-being
Named on the company’s own website, read SEP 9, 2026
CareersCareers page — seen SEP 9, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
31 US patents granted 2010–2025, 15 of them in the five years to SEP 2025.
Pharmaceuticals 31
- Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatmentUS 12,403,146 · granted SEP 2, 2025
- Emulsion formulationsUS 12,357,643 · granted JUL 15, 2025
- Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterolsUS 12,295,961 · granted MAY 13, 2025
- Ganaxolone for use in treating tuberous sclerosis complex and seizure disordersUS 12,268,696 · granted APR 8, 2025
- Ganaxolone for use in treatment of status epilepticusUS 12,246,026 · granted MAR 11, 2025
Newest 5 shown · Granted to Marius Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Marius Pharmaceuticals, INC. | Raleigh | NC | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.